92 results on '"Proteasome Inhibitors"'
Search Results
2. Advancements in drugs restructured with nanomedicines for multiple myeloma treatment
3. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects
4. Real-world incidence and risk factors of bortezomib-related cardiovascular adverse events in patients with multiple myeloma
5. Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors
6. Efficacy and Safety of Weekly Bortezomib-dexamethasone as the Third-Line Therapy for Warm Autoimmune Hemolytic Anemia: a Case Series of 5 Patients
7. Gastrointestinal toxicities of proteasome inhibitor therapy
8. Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea
9. Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs
10. Gastric cancer cell types display distinct proteasome/immunoproteasome patterns associated with migration and resistance to proteasome inhibitors
11. Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma
12. SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
13. Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents
14. Molecular Cardiotoxic Effects of Proteasome Inhibitors Carfilzomib and Ixazomib and Their Combination with Dexamethasone Involve Mitochondrial Dysregulation
15. Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs
16. NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1
17. Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature
18. Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors
19. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
20. Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems
21. Emerging cancer therapies and cardiovascular risk
22. Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas
23. Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019
24. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells
25. Tetrazolium reduction assays under-report cell death provoked by clinically relevant concentrations of proteasome inhibitors
26. Moving Toward Continuous Therapy in Multiple Myeloma
27. An Infection Hypothesis of Parkinson’s Disease
28. Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent
29. Diagnostische und therapeutische Betrachtungen zum Rezidiv des multiplen Myeloms: Eine aktuelle Übersicht
30. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey
31. Diagnostische und therapeutische Betrachtungen zum Rezidiv des multiplen Myeloms: Eine aktuelle Übersicht
32. Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs
33. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib
34. Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide
35. Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies
36. Positioning of proteasome inhibitors in therapy of solid malignancies
37. Multiples Myelom: Was ist gesichert in der Therapie?
38. The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities
39. Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors
40. Update on Chemotherapy-Induced Peripheral Neuropathy
41. Proteasome inhibitors against amelanotic melanoma
42. Glioma‐derived cancer stem cells are hypersensitive to proteasomal inhibition
43. MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
44. Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention
45. Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
46. The effects of proteasomal inhibition on synaptic proteostasis
47. Primary Plasma Cell Leukemia: Identity Card 2016
48. Discovery of new M y c o b a c t e r i u m t u b e r c u l o s i s proteasome inhibitors using a knowledge-based computational screening approach
49. A Quantitative Method to Monitor the Efficacy of Inhibitors Against the Chymotrypsin-Like Activity of the Proteasome in Tobacco Leaf Protoplasts
50. Current therapeutic strategies for multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.